BA
ALDX icon

BlackRock Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

BlackRock Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$16K Hold
2,978
– – ﹤0.01% 3496
2016
Q3 		$23K Hold
2,978
– – ﹤0.01% 3416
2016
Q2 		$17K Hold
2,978
– – ﹤0.01% 3476
2016
Q1 		$12K Hold
2,978
– – ﹤0.01% 3540
2015
Q4 		$20K Hold
2,978
– – ﹤0.01% 3488
2015
Q3 		$17K Buy
2,978
+1,794
+152% +$14K ﹤0.01% 3549
2015
Q2 		$9K Buy
+1,184
New +$10.2K ﹤0.01% 3622

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock Advisors's ALDX Position: Q4 2016 in Review

BlackRock Advisors held its Aldeyra Therapeutics (ALDX) position steady in Q4 2016 at 2,978 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #3496.

BlackRock Advisors first reported a position in ALDX in Q2 2015 and has held it in 7 quarters since. The position peaked at $23K in Q3 2016. 20 funds tracked by Wall St. Rank hold ALDX as of Q4 2016.

  • BlackRock Advisors held 2,978 shares of Aldeyra Therapeutics worth $16K as of Q4 2016.
  • BlackRock Advisors left its Aldeyra Therapeutics share count unchanged in Q4 2016.
  • Aldeyra Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3496 holding.
  • BlackRock Advisors first reported a position in Aldeyra Therapeutics in Q2 2015 and has held it in 7 quarters since.
  • BlackRock Advisors's Aldeyra Therapeutics position peaked at $23K in Q3 2016.
  • 20 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.